OncoMatch/Clinical Trials/NCT06684639

A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma

Is NCT06684639 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies GD2-CAR-T cell for neuroblastoma.

Early Phase 1RecruitingThe General Hospital of Western Theater CommandNCT06684639Data as of May 2026

Treatment: GD2-CAR-T cell — Neuroblastoma (NB) is a malignant tumor of the sympathetic nervous system.Chemotherapy and autologous hematopoietic stem cell transplantation are the main treatments for neuroblastoma, and the prognosis of patients with high-risk recurrence and refractory treatment is very poor. There is a large unmet medical need in patients with relapsed refractory neuroblastoma, and further research into new therapeutic approaches is needed for these patients.GD2 is a dissialic ganglioside expressed by neuroectodermal tumors. The proportion of GD2 expression in neuroblastoma is up to 100%, so GD2 is a specific target for neuroblastoma immunotherapy and an ideal target for CAR-T treatment of neuroblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Biomarker criteria

Required: GD2 overexpression (positive expression)

positive expression of GD2 antigen in tumor cells

Performance status

ECOG 0–3(Limited self-care)

Lab requirements

Kidney function

creatinine clearance (estimated by the Cockcroft Gault formula) > 60 mL/min

Liver function

Serum ALT/AST ≤ 2.5 ULN; Total bilirubin ≤1.5 ULN, excluding subjects with Gilbert's syndrome

Cardiac function

Cardiac ejection fraction ≥ 50%, echocardiography confirmed centropericardial effusion, and ECG showed no clinically significant abnormal findings. There was no clinically significant pleural effusion.

Adequate kidney, liver, lung and heart function, defined as creatinine clearance (estimated by the Cockcroft Gault formula) > 60 mL/min; Serum ALT/AST ≤ 2.5 ULN; Total bilirubin ≤1.5 ULN, excluding subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 50%, echocardiography confirmed centropericardial effusion, and ECG showed no clinically significant abnormal findings. There was no clinically significant pleural effusion. Baseline blood oxygen saturation under indoor ventilation was > 92%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify